Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level, screening potential new therapeutics, and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
As a the first and only market research firm to specialize in the stem cell industry, BioInformant has released the “Global Induced Pluripotent Stem Cell (iPSC) Industry Report.” Published May 2020, this 238 page global strategic report provides breaking coverage of the global iPSC market, including the effects of the COVID-19 pandemic on this rapidly evolving stem cell sector. [Read more…]
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerging during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cells types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
Heard about iPS cells, but don’t know exactly what they are and what they can do? Read on to find out more.
In this article:
- What Are IPS Cells?
- How Are IPS Stem Cells Produced?
- What Are the Advantages of IPS Cells Over ES Cells?
- Are IPS Cells Similar to ES Cells?
- What Are the Risks of IPS Cell Use?
- What Are the Challenges in IPS Cell Research?
- Do IPS Cells Have the Potential for Medical Applications?
Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.